Invention Grant
- Patent Title: Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment
-
Application No.: US14214040Application Date: 2014-03-14
-
Publication No.: US11235037B2Publication Date: 2022-02-01
- Inventor: Robert Almassy , Richard E. Showalter , James A. Thomson , Wes Sisson , Wei-Jong Shia , Li-Chang Chen , Yang Lee
- Applicant: Polaris Group
- Applicant Address: KY Grand Cayman
- Assignee: Polaris Group
- Current Assignee: Polaris Group
- Current Assignee Address: KY Grand Cayman
- Agency: Carter, DeLuca & Farrell LLP
- Main IPC: A61K38/50
- IPC: A61K38/50 ; C12N9/78 ; A61K45/06
Abstract:
The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
Public/Granted literature
- US20140348814A1 ARGINNE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT Public/Granted day:2014-11-27
Information query
IPC分类:
